JCR Pharmaceuticals Co., Ltd.

Quick facts

Phase 3 pipeline

• JR-141 · Rare genetic/lysosomal storage disorders
  JR-141 is a recombinant human arylsulfatase A enzyme designed to cross the blood-brain barrier and replace deficient enzyme activity in lysosomal storage disorders.
• JR-141 or Idursulfase · Rare genetic disease / Lysosomal storage disorder
  JR-141 is a recombinant idursulfase enzyme that replaces deficient iduronate-2-sulfatase to break down glycosaminoglycans in Hunter syndrome.

Phase 1 pipeline

• JR-171
• JR-441
• JR-446

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• JCR Pharmaceuticals Co., Ltd. portfolio CI brief
• JCR Pharmaceuticals Co., Ltd. pipeline updates RSS